We have seen and will continue to see dramatic changes within the field of oncology. Whilst the burden of disease is set to increase, the available armamentarium to the oncologist will be greater, more robust and offer the potential to focus on individual needs. Future Oncology provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic, policy and real world issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, with strong relevance to the clinical setting.
Topics addressed include:
Profiles of new anticancer agents
Protocols of on-going studies
Selective and 'personalized' approaches
Clinical implications and applications for new immunotherapies, radiotherapies and biomarkers
Integration of diagnostic and therapeutic approaches
Impact of molecular genetics on prevention, screening, diagnosis and treatment
Screening programs and methodology
Biological processes involved in cancer and how new understanding will impact treatment
Current debates on policy and treatment guidelines
Real world data and outcomes research
Journal metrics
Citation metrics
3.0 (2023) Impact Factor
Q2 Impact Factor Best Quartile
2.9 (2023) 5 year IF
5.4 (2023) CiteScore (Scopus)
Q2 CiteScore Best Quartile
0.655 (2023) SNIP
1.029 (2023) SJR
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors
who are deciding where to submit their next manuscript for publication.
However, any one metric only tells a part of the story of a journal’s
quality and impact. Each metric has its limitations which means that it
should never be considered in isolation, and metrics should be used to
support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside
other qualitative factors such as a journal’s aims & scope, its
readership, and a review of past content published in the journal. In
addition, a single article should always be assessed on its own merits and
never based on the metrics of the journal it was published in.
Usage and acceptance rate data above are for the last full calendar year
and are updated annually in February. Speed data is updated every six
months, based on the prior six months. Citation metrics are updated
annually mid-year. Please note that some journals do not display all of
the following metrics
(find out why).
Usage:
the total number of times articles in the journal were viewed by users
of Taylor & Francis Online in the previous calendar year, rounded to the
nearest thousand.
Citation Metrics
Impact Factor*:
the average number of citations received by articles published in the
journal within a two-year window. Only journals in the Clarivate Science
Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI),
Arts and Humanities Citation Index (AHCI) and the Emerging Sources
Citation Index (ESCI) have an Impact Factor.
Impact Factor Best Quartile*:
the journal’s highest subject category ranking in the Journal Citation
Reports. Q1 = 25% of journals with the highest Impact Factors.
5 Year Impact Factor*:
the average number of citations received by articles in the journal
within a five-year window.
CiteScore (Scopus)†:
the average number of citations received by articles in the journal over
a four-year period.
CiteScore Best Quartile†:
the journal’s highest CiteScore ranking in a Scopus subject category. Q1
= 25% of journals with the highest CiteScores.
SNIP
(Source Normalized Impact per Paper):
the number of citations per paper in the journal, divided by citation
potential in the field.
SJR
(Scimago Journal Rank):
Average number of (weighted) citations in one year, divided by the
number of articles published in the journal in the previous three years.
Speed/acceptance
From submission to first decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision. Based on manuscripts receiving a
first decision in the last six months.
From submission to first post-review decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision if it is sent out for peer review.
Based on manuscripts receiving a post-review first decision in the last
six months.
From acceptance to online publication:
the average (median) number of days from acceptance of a manuscript to
online publication of the Version of Record. Based on articles published
in the last six months.
Acceptance rate:
articles accepted for publication by the journal in the previous
calendar year as percentage of all papers receiving a final decision.
Senior Editors Jackson Orem: Uganda Cancer Institute, Africa Ron Allison: 21st Century Oncology, USA
Editorial Advisory Board Philip Arlen: Precision Biologics, USA Lev M. Berstein: Petrov Research Institute of Oncology, St. Petersburg, Russia Alba Brandes: AUSL Bologna, Italy Isidoro di Carlo: University of Catania, Italy Claudio Cerchione: IRCCS Istituto Romagnolo per lo Studio dei Tumori, Italy Liang Cheng: Indiana University School of Medicine, USA Doriano Fabpo: Cellestia, Switzerland Ahmet Emre Eşkazan: Istanbul University-Cerrahpaşa, Turkey Stefano Fanti: University of Bologna, Italy Gianluca Franceschini: Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Italy Martin Gleave: University of British Columbia, Canada Ajay Goel: Baylor University Medical Center, USA Michael Grynberg: Hôpital Antoine Béclère, France Nadia Harbeck: peast Center, University of Munich (LMU), Germany Mieke Van Hemelrijck: King's College London, UK Robin Jones: The Royal Marsden, UK Nathan Lawrentschuk: University of Melbourne, Australia Nicholas Lemoine: Barts Cancer Institute, UK Simon Lo: University of Catania, University of Washington, USA Laleh Melstrom: City of Hope Medical Center, USA Suneel Mundle: Rush University Medical Center, USA Edith Perez: Mayo Clinic, USA Juergen Reichardt: Yachay Tech University, Ecuador Rafael Rosell: Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Spain Jeffrey Ross: Albany Medical Center, USA Dimitrios Roukos: University of Ioannina, Greece Giorgio Scagliotti: University of Torino, Italy Hans-Joachim Schmoll: University Clinic Halle, Germany Gary Schwartz: University of North Dakota, USA Giuseppe Tonini: Campus Bio Medico University Hospital Rome, Italy Paul Workman: Cancer Research UK Cancer Therapeutics Unit, UK Pranav S. Apaham; Bristol Myers Squibb Lei Huang; German Research Cancer Centre (DKFZ) Krishna M. Irrinki; Mount Sinai Hospital Christian Jackisch; Sana Klinikum Offenbach GmbH Shalini Makawita; Baylor College of Medicine Kelly E. McCann; University of California, Los Angeles Rowan E. Miller; University College London Hospitals Yusuke Okuma; National Cancer Center, Japan Stefano Rausei; ASST Valle Olona Antonio G. Solimando; University of Bari Aldo Moro Francesco Tovoli; University of Bologna Caroline Watts; University of Sydney Weinan Xue; Harbin Medical University Monal Yuwanati; Saveetha Institute of Medical and Technical Sciences
Open access
Future Oncology is a hybrid open access journal that is part of our Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
Increase the discoverability and readership of your article
Make an impact and reach new readers, not just those with easy access to a research library
Freely share your work with anyone, anywhere
Comply with funding mandates and meet the requirements of your institution, employer or funder
Rigorous peer review for every open access article
Article Publishing Charges (APC)
If you choose to publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis.
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors, make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110817/Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
![F1000Research. The Oncology Gateway. Accepting multiple article types. Submit now.]({"type":"image" , "src" : "/sda/112413/JournalAd-F1000-Oncology.jpg"})